Lexeo Therapeutics, Inc.

LXEO Healthcare Biotechnology

Lexeo Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $654,000.00. In the quarter to June 2026, EPS grew 50.0%, free cash flow grew 35.6% and total debt fell 83.5%, each against the same quarter a year earlier.

2.64 0.12 −4.35%
Market cap
$226.6M
P/E
0.0×
Fwd P/E
−3.1×
Dividend yield
—
F-score
4/9
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
13.89 14.16 11.21 7.40
Net Debt/EBITDA
7.58 8.65 7.88 5.68
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.21) (0.26) (0.37) (0.49)
Book value per Share
2.75 2.85 4.60 1.98
Free Cash Flow
(17.60) (21.18) (20.08) (29.84)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates